secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-054475
Event type: earnings
Sentiment:  negative
Materiality: 0.78
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q1 revenue $51.1M (+21% YoY), cuts FY2024 guidance to $201-$211M
-------------------------------------------------------------------------------

- Q1 revenue $51.1M (+21% YoY); net loss $18.7M ($0.30/share) vs $13.5M loss in Q1 2023.
- FY2024 revenue guidance slashed to $201-$211M from $220-$225M, citing increased MIS Osteotomy competition and knockoffs.
- Adjusted EBITDA loss improved to $8.3M in Q1 from $10.0M in prior year.
- CEO plans two new 3D MIS Osteotomy launches later in 2024 to counter competitive headwinds.
- Cash and marketable securities $112.1M; 63 granted US patents as of March 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024054475/0000950170-24-054475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024054475/tmci-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer